JP2023534720A5 - - Google Patents
Info
- Publication number
- JP2023534720A5 JP2023534720A5 JP2023504330A JP2023504330A JP2023534720A5 JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5 JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023504330 A JP2023504330 A JP 2023504330A JP 2023534720 A5 JP2023534720 A5 JP 2023534720A5
- Authority
- JP
- Japan
- Prior art keywords
- intron
- antisense oligonucleotide
- sequence
- seq
- target region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020902550 | 2020-07-22 | ||
| AU2020902550A AU2020902550A0 (en) | 2020-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A | |
| PCT/AU2021/050788 WO2022016222A1 (en) | 2020-07-22 | 2021-07-22 | Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534720A JP2023534720A (ja) | 2023-08-10 |
| JP2023534720A5 true JP2023534720A5 (cg-RX-API-DMAC10.html) | 2024-07-18 |
Family
ID=79729542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504330A Pending JP2023534720A (ja) | 2020-07-22 | 2021-07-22 | Scn2a中の機能喪失変異に関連する障害を処置するための組成物及び方法 |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250146073A1 (en) * | 2022-02-04 | 2025-05-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of scn2a-related disorders |
| KR20250180156A (ko) | 2024-06-21 | 2025-12-31 | 중앙대학교 산학협력단 | 뇌전증의 예방 또는 치료용 조성물, 및 뇌전증 치료제 스크리닝 방법과 이의 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1846501A (en) * | 1999-11-26 | 2001-06-04 | Bionomics Limited | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| WO2002006294A2 (en) * | 2000-07-13 | 2002-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the mmp13 gene |
| WO2005035784A1 (en) * | 2003-10-13 | 2005-04-21 | Bionomics Limited | A diagnostic method for neonatal or infantile epilepsy syndromes |
| CN101148665A (zh) * | 2005-12-05 | 2008-03-26 | 广州医学院第二附属医院 | 钠离子通道scn1a基因突变及基因突变检测方法和用途 |
| ES2618894T3 (es) * | 2009-06-24 | 2017-06-22 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2 |
| US9364495B2 (en) * | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
| WO2013173637A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| GB201410693D0 (en) * | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3481857B1 (en) * | 2016-07-06 | 2026-02-11 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| KR20190030833A (ko) * | 2017-09-15 | 2019-03-25 | 가톨릭대학교 산학협력단 | 신장암 환자의 예후 진단 및 치료 전략 결정용 연령 특이적 마커 |
| LT3700570T (lt) * | 2017-10-23 | 2025-04-10 | Stoke Therapeutics, Inc. | Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui |
| WO2019143831A1 (en) * | 2018-01-17 | 2019-07-25 | Rogcon U.R., Inc. | Compositions and methods for increasing expression of scn2a |
| CA3110211A1 (en) * | 2018-08-20 | 2020-02-27 | Rogcon, Inc. | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies |
| US20220090087A1 (en) * | 2019-01-23 | 2022-03-24 | The Florey Institute Of Neuroscience And Mental Health | Antisense oligonucleotides targeting scn2a retained introns |
-
2021
- 2021-07-22 CN CN202180064122.5A patent/CN116368227A/zh active Pending
- 2021-07-22 JP JP2023504330A patent/JP2023534720A/ja active Pending
- 2021-07-22 IL IL299999A patent/IL299999A/en unknown
- 2021-07-22 PE PE2023000101A patent/PE20230982A1/es unknown
- 2021-07-22 EP EP21845305.8A patent/EP4185697A4/en active Pending
- 2021-07-22 KR KR1020237005996A patent/KR20230095056A/ko active Pending
- 2021-07-22 MX MX2023000907A patent/MX2023000907A/es unknown
- 2021-07-22 WO PCT/AU2021/050788 patent/WO2022016222A1/en not_active Ceased
- 2021-07-22 AU AU2021311137A patent/AU2021311137A1/en active Pending
- 2021-07-22 CA CA3186629A patent/CA3186629A1/en active Pending
- 2021-07-22 US US18/005,800 patent/US20230272387A1/en active Pending
- 2021-07-22 BR BR112023000988A patent/BR112023000988A2/pt unknown
-
2023
- 2023-01-20 CL CL2023000208A patent/CL2023000208A1/es unknown
- 2023-02-21 CO CONC2023/0001922A patent/CO2023001922A2/es unknown
- 2023-02-22 EC ECSENADI202312641A patent/ECSP23012641A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morihiro et al. | Biological applications of xeno nucleic acids | |
| JP7478923B2 (ja) | シュードウリジン化のための核酸分子 | |
| WO2020198509A2 (en) | Modified oligonucleotides with increased stability | |
| JP6813506B2 (ja) | レーバー先天性黒内障のためのオリゴヌクレオチド療法 | |
| JP2021533804A5 (cg-RX-API-DMAC10.html) | ||
| TW201726918A (zh) | 抑制lpa之基因表現之組合物及方法 | |
| EP3234134A1 (en) | Targeted rna editing | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| CA3118167A1 (en) | Bispecific antisense oligonucleotides for dystrophin exon skipping | |
| WO2022217366A1 (en) | Modified oligonucleotides for the treatment of duchenne muscular dystrophy | |
| BR112020010090A2 (pt) | oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos | |
| JP2023518268A5 (cg-RX-API-DMAC10.html) | ||
| JP2024543000A (ja) | 操作されたrna | |
| KR20250125967A (ko) | 진보된 rna 표적화 (arnatar) | |
| US20250313832A1 (en) | Compositions for treating syngap-1 related neurodevelopmental disorders | |
| JP2024522272A5 (cg-RX-API-DMAC10.html) | ||
| JP2024542738A5 (cg-RX-API-DMAC10.html) | ||
| JP2023534720A (ja) | Scn2a中の機能喪失変異に関連する障害を処置するための組成物及び方法 | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股dna及其應用 | |
| JP2024520555A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2019004420A1 (ja) | ヘテロ二本鎖型antimiR | |
| CA3173399A1 (en) | Bifunctional molecules and methods of using thereof | |
| WO2020171149A1 (ja) | ヘテロ核酸の最適ps修飾パターン | |
| BR112020012427A2 (pt) | oligonucleotídeo, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, processo para a fabricação de um oligonucleotídeo, oligonucleotídeo fabricado e invenção | |
| CN121127248A (zh) | 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法 |